This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yen, L. Articles by Carraway, K. L. Search for Related Content PubMed PubMed Citation Articles by Yen, L. Articles by Carraway, K. L., III

Loss of Nrdp1 Enhances ErbB2/ErbB3–Dependent Breast Tumor Cell Growth

¹ University of California Davis Cancer Center; ² Department of Pathology and Laboratory Medicine, School of Medicine; and ³ Center for Comparative Medicine, University of California, Davis, Sacramento, California

Requests for reprints: Kermit L. Carraway III, University of California Davis Cancer Center, University of California Davis Medical Center Research Building III, 4645 2nd Avenue, Sacramento, CA 95817-2305. Phone: 916-734-3114; Fax: 916-734-0190; E-mail: klcarraway{at}ucdavis.edu.

Dysregulation of ErbB receptor tyrosine kinases is thought to promote mammary tumor progression by stimulating tumor cell growth and invasion. Overexpression and aberrant activation of ErbB2/HER2 confer aggressive and malignant characteristics to breast cancer cells, and patients displaying ErbB2-amplified breast cancer face a worsened prognosis. Recent studies have established that ErbB2 and ErbB3 are commonly co-overexpressed in breast tumor cell lines and in patient samples. ErbB2 heterodimerizes with and activates the ErbB3 receptor, and the two receptors synergize in promoting growth factor–induced cell proliferation, transformation, and invasiveness. Our previous studies have shown that the neuregulin receptor degradation protein-1 (Nrdp1) E3 ubiquitin ligase specifically suppresses cellular ErbB3 levels by marking the receptor for proteolytic degradation. Here, we show that overexpression of Nrdp1 in human breast cancer cells results in the suppression of ErbB3 levels, accompanied by the inhibition of cell growth and motility and the attenuation of signal transduction pathways. In contrast, either Nrdp1 knockdown or the overexpression of a dominant-negative form enhances ErbB3 levels and cellular proliferation. Additionally, Nrdp1 expression levels inversely correlate with ErbB3 levels in primary human breast cancer tissue and in a mouse model of ErbB2 mammary tumorigenesis. Our observations suggest that Nrdp1-mediated ErbB3 degradation suppresses cellular growth and motility, and that Nrdp1 loss in breast tumors may promote tumor progression by augmenting ErbB2/ErbB3 signaling. (Cancer Res 2006; 66(23): 11279-86)

This article has been cited by other articles:

				H. C. Workman, C. Sweeney, and K. L. Carraway III The Membrane Mucin Muc4 Inhibits Apoptosis Induced by Multiple Insults via ErbB2-Dependent and ErbB2-Independent Mechanisms Cancer Res., April 1, 2009; 69(7): 2845 - 2852. [Abstract] [Full Text] [PDF]

				J. K. Miller, D. L. Shattuck, E. Q. Ingalla, L. Yen, A. D. Borowsky, L. J.T. Young, R. D. Cardiff, K. L. Carraway III, and C. Sweeney Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast Cancer Cancer Res., October 15, 2008; 68(20): 8286 - 8294. [Abstract] [Full Text] [PDF]

				Z. Cao, X. Wu, L. Yen, C. Sweeney, and K. L. Carraway III Neuregulin-Induced ErbB3 Downregulation Is Mediated by a Protein Stability Cascade Involving the E3 Ubiquitin Ligase Nrdp1 Mol. Cell. Biol., March 15, 2007; 27(6): 2180 - 2188. [Abstract] [Full Text] [PDF]